November 15, 2024
Avicanna Reports Q3 2024
9-month revenue of $18.8 million, representing a 75% increase from 2023. Consolidated Gross Margins of 57%, during Q3 2024. TORONTO,…
Pharmaceuticals, Biotechnology and Life Sciences
9-month revenue of $18.8 million, representing a 75% increase from 2023. Consolidated Gross Margins of 57%, during Q3 2024. TORONTO,…
Key Takeaways: Since its founding in 2020, Tevogen Bio has developed a significant asset portfolio, and kept expenditures under $40…
SALINAS, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) — Lowell Farms Inc. (the “Company”) (CSE: LOWL; OTCQX: LOWLF), a California cannabis…
Outcomes at 12 months demonstrate a statistically significant net treatment effect of 19% compared to the standard of care two-stage…
MIRAMAR, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage…
-Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second…
$13.9 million in gross proceeds raised since the beginning of 2024 extending expected cash runway into mid Q1 2025 and…
– Secures $3.2m in PIPE Financing — $50m Term Sheet Obtained for Available Financing under Equity Line of Credit –…
BERKELEY HEIGHTS, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”),…
FORT WORTH, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (Nasdaq: TFFP) today announced that the Company has…